Revealing different roles of the mTOR-targets S6K1 and S6K2 in breast cancer by expression profiling and structural analysis

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Karlsson, Elin ^a   Magić, Ivana ^a   Bostner, Josefine ^a   Dyrager, Christine ^a   Lysholm, Fredrik ^a   Hallbeck, Anna Lotta ^a   Stål, Olle ^a   Lundström, Patrik ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; S6 KINASE; S6 KINASE 1; S6 KINASE 2; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TRANSCRIPTION FACTOR E2F1; TUMOR MARKER; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOWN REGULATION; ENZYME REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SILENCING; GENETIC CORRELATION; GENOME; HUMAN; IN VITRO STUDY; ONCOGENE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; UPREGULATION; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR MODEL; MORTALITY; PATHOLOGY; PROTEIN CONFORMATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84957573254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145013     Document Type: Article

References (56)

1. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35. doi: 10.1038/nrm3025 PMID: 21157483
2. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. PMID: 15718470
3. Laplante M, Sabatini DM (2012) mTOR Signaling in Growth Control and Disease. Cell 149: 274-293. doi: 10.1016/j.cell.2012.03.017 PMID: 22500797
4. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643. doi: 10.1038/nrc2713 PMID: 19701242
5. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529. doi: 10.1056/NEJMoa1109653 PMID: 22149876
6. Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441: 1-21. doi: 10.1042/BJ20110892 PMID: 22168436
7. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, James CD (1999) Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 59: 1408-1411. PMID: 10197603
8. Karlsson E, Perez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, et al. (2013) The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res 15: R96. PMID: 24131622
9. Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, et al. (2011) Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat 126: 93-99. doi: 10.1007/s10549-010-1315-z PMID: 21184268
10. Perez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, et al. (2011) Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat 128: 713-723. doi: 10.1007/s10549-010-1058-x PMID: 20953835
11. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al. (2007) 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67: 7551-7555. PMID: 17699757
12. Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olsson B, Hallbeck AL, et al. (2011) High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes, chromosomes & cancer 50: 775-787.
13. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, et al. (2012) Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14: R138. doi: 10.1186/bcr3343 PMID: 23102376
14. Pardo OE, Seckl MJ (2013) S6K2: The Neglected S6 Kinase Family Member. Frontiers in oncology 3: 191. doi: 10.3389/fonc.2013.00191 PMID: 23898460
15. Sridharan S, Basu A (2011) S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Res 71: 2590-2599. doi: 10.1158/0008-5472.CAN-10-3253 PMID: 21427355
16. Gout I, Minami T, Hara K, Tsujishita Y, Filonenko V, Waterfield MD, et al. (1998) Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region. J Biol Chem 273: 30061-30064. PMID: 9804755
17. Grove JR, Banerjee P, Balasubramanyam A, Coffer PJ, Price DJ, Avruch J, et al. (1991) Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol 11: 5541-5550. PMID: 1922062
18. Lee-Fruman KK, Kuo CJ, Lippincott J, Terada N, Blenis J (1999) Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene 18: 5108-5114. PMID: 10490847
19. Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Sabatini DM, et al. (1998) Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proc Natl Acad Sci U S A 95: 8351-8356. PMID: 9653190
20. Zhou D, Ye JJ, Li Y, Lui K, Chen S (2006) The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha. Nucleic Acids Res 34: 5974-5986. PMID: 17068076
21. Fenton TR, Gout IT (2010) Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43: 47-59. doi: 10.1016/j.biocel.2010.09.018 PMID: 20932932
22. Sunami T, Byrne N, Diehl RE, Funabashi K, Hall DL, Ikuta M, et al. (2010) Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem 285: 4587-4594. doi: 10.1074/jbc.M109.040667 PMID: 19864428
23. Wang J, Zhong C, Wang F, Qu F, Ding J (2013) Crystal structures of S6K1 provide insights into the regulation mechanism of S6K1 by the hydrophobic motif. Biochem J 454: 39-47. doi: 10.1042/BJ20121863 PMID: 23731517
24. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555. PMID: 16141321
25. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964. PMID: 16280042
26. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009. PMID: 12490681
27. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607. doi: 10.1038/nature11003 PMID: 22460905
28. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264. PMID: 12925520
29. Blundell TL, Sibanda BL, Sternberg MJ, Thornton JM (1987) Knowledge-based prediction of protein structures and the design of novel molecules. Nature 326: 347-352. PMID: 3550471
30. Maiti R, Van Domselaar GH, Zhang H, Wishart DS (2004) SuperPose: a simple server for sophisticated structural superposition. Nucleic acids research 32: W590-594. PMID: 15215457
31. Reimand J, Arak T, Vilo J (2011) g:Profiler - a web server for functional interpretation of gene lists (2011 update). Nucleic acids research 39: W307-315. doi: 10.1093/nar/gkr378 PMID: 21646343
32. Reimand J, Kull M, Peterson H, Hansen J, Vilo J (2007) g:Profiler - a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic acids research 35: W193-200. PMID: 17478515
33. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169. doi: 10.1038/nrc3215 PMID: 22337149
34. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J, et al. (2010) Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 431: 245-255. doi: 10.1042/BJ20101024 PMID: 20704563
35. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, et al. (2000) Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408: 994-997. PMID: 11140689
36. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124. PMID: 15060135
37. Julien LA, Carriere A, Moreau J, Roux PP (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30: 908-921. doi: 10.1128/MCB.00601-09 PMID: 19995915
38. Arnason T, Pino MS, Yilmaz O, Kirley SD, Rueda BR, Chung DC, et al. (2013) Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc (Min) mice. Cancer biology & therapy 14: 672-678.
39. Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, et al. (2011) Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocrine-related cancer 18: 565-577. doi: 10.1530/ERC-10-0046 PMID: 21734071
40. Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, et al. (2011) A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71: 6773-6784. doi: 10.1158/0008-5472.CAN-11-1295 PMID: 21908557
41. Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, et al. (2013) Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. The pharmacogenomics journal.
42. Yu Z, Gao W, Jiang E, Lu F, Zhang L, Shi Z, et al. (2013) Interaction between IGF-IR and ER Induced by E2 and IGF-I. PLoS One 8: e62642. doi: 10.1371/journal.pone.0062642 PMID: 23704881
43. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318. doi: 10.1038/nrm2672 PMID: 19339977
44. Rosner M, Hengstschlager M (2011) Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene.
45. Rossi R, Pester JM, McDowell M, Soza S, Montecucco A, Lee-Fruman KK (2007) Identification of S6K2 as a centrosome-located kinase. FEBS letters 581: 4058-4064. PMID: 17678899
46. Ruvinsky I, Meyuhas O (2006) Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31: 342-348. PMID: 16679021
47. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK (2009) S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 284: 6361-6369. doi: 10. 1074/jbc.M807532200 PMID: 19112174
48. Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D, et al. (2010) Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway. J Biol Chem 285: 17065-17076. doi: 10.1074/jbc.M109.078782 PMID: 20308064
49. Han SP, Tang YH, Smith R (2010) Functional diversity of the hnRNPs: past, present and perspectives. Biochem J 430: 379-392. doi: 10.1042/BJ20100396 PMID: 20795951
50. Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, et al. (2008) Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. Rna 14: 1318-1327. doi: 10.1261/rna.950608 PMID: 18515545
51. Engelmann D, Putzer BM (2012) The dark side of E2F1: in transit beyond apoptosis. Cancer Res 72: 571-575. doi: 10.1158/0008-5472.CAN-11-2575 PMID: 22298593
52. Real S, Meo-Evoli N, Espada L, Tauler A (2011) E2F1 regulates cellular growth by mTORC1 signaling. PLoS One 6: e16163. doi: 10.1371/journal.pone.0016163 PMID: 21283628
53. Zhou W, Srinivasan S, Nawaz Z, Slingerland JM (2013) ERalpha, SKP2 and E2F-1 form a feed forward loop driving late ERalpha targets and G1 cell cycle progression. Oncogene.
54. Louie MC, McClellan A, Siewit C, Kawabata L (2010) Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Molecular cancer research: MCR 8: 343-352. doi: 10.1158/1541-7786.MCR-09-0395 PMID: 20215421
55. Taylor SS, Kornev AP (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36: 65-77. doi: 10.1016/j.tibs.2010.09.006 PMID: 20971646
56. Williamson M (2012) How proteins work. Garland Science.